trending Market Intelligence /marketintelligence/en/news-insights/trending/tmds_rhbasuc2tbnirfhlq2 content esgSubNav
In This List

MyoKardia starts common stock offering

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


MyoKardia starts common stock offering

MyoKardia Inc. started a proposed underwritten public offering of 3,750,000 common shares.

The South San Francisco, Calif.-based biopharmaceutical company said it intends to grant the underwriters an option to buy an additional 562,500 shares.

MyoKardia plans to use the net proceeds from the offering plus additional cash to fund research and development activities and for working capital and other general corporate purposes.

J.P. Morgan Securities, Bank of America Merrill Lynch, Credit Suisse and Wells Fargo Securities are acting as joint book-running managers for the proposed offering.